Skip to content

Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy

Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03142425
Enrollment
150
Registered
2017-05-05
Start date
2017-06-19
Completion date
2019-12-31
Last updated
2019-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiation Therapy

Brief summary

Collect blood samples and associated clinical data prior to and post radiation treatment.

Detailed description

Exploratory study to collect paired pre- and post-irradiation blood samples from 150 participants.

Interventions

None listed

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
DxTerity Diagnostics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male and female patients age 18 or older 2. Diagnosed with a primary rectal or esophageal cancer 3. Planned radiation therapy to the esophagogastric area to a minimum of 4140 cGy for esophageal/gastroesophageal junction cancer or to pelvis to a minimum of 4500 cGy for rectal cancer as part of clinical care 4. Combining chemotherapy is allowed 5. ECOG Performance Status 0-2 6. Able to provide written informed consent

Exclusion criteria

1. Subjects who have received radiation within three (3) months to esophagogastric or pelvic areas prior to consent 2. Subjects, who in the opinion of the investigator, may not be able to comply with the requirements of the study

Design outcomes

Primary

MeasureTime frameDescription
Collection of blood samples from patients prior to and post irradiation treatment.Up to 4 months, from informed consent through follow up activities.Explore and validate a radiation sensitivity test for determining radiation treatment tumor response by refining and analyzing gene expression signature of blood samples collected from 150 patients prior to and post irradiation treatment.

Countries

United States

Contacts

Primary ContactAndrea Arruda, B.S.
aarruda@dxterity.com310-537-7857
Backup ContactKristen Warren, B.S.
kwarren@dxterity.com310-537-7857

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026